October 8, 2015 / 5:20 AM / 2 years ago

BRIEF-FDA grants Pharming Group RUCONEST 12-year reference exclusivity

1 Min Read

Oct 8 (Reuters) - Pharming Group NV :

* Announces that the U.S. Food and Drug Administration (FDA) has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor ) 50 IU/kg Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below